CA2962117C - Pulmonary administration of pyocins for treating bacterial respiratory infections - Google Patents

Pulmonary administration of pyocins for treating bacterial respiratory infections Download PDF

Info

Publication number
CA2962117C
CA2962117C CA2962117A CA2962117A CA2962117C CA 2962117 C CA2962117 C CA 2962117C CA 2962117 A CA2962117 A CA 2962117A CA 2962117 A CA2962117 A CA 2962117A CA 2962117 C CA2962117 C CA 2962117C
Authority
CA
Canada
Prior art keywords
pyocin
pyocins
type
subject
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2962117A
Other languages
English (en)
French (fr)
Other versions
CA2962117A1 (en
Inventor
Daniel Walker
Laura MCCAUGHEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Original Assignee
University of Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow filed Critical University of Glasgow
Publication of CA2962117A1 publication Critical patent/CA2962117A1/en
Application granted granted Critical
Publication of CA2962117C publication Critical patent/CA2962117C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2962117A 2014-09-23 2015-09-22 Pulmonary administration of pyocins for treating bacterial respiratory infections Active CA2962117C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1416788.6 2014-09-23
GBGB1416788.6A GB201416788D0 (en) 2014-09-23 2014-09-23 Therapeutic applications for pyocins
PCT/EP2015/071768 WO2016046218A1 (en) 2014-09-23 2015-09-22 Pulmonary administration of pyocins for treating bacterial respiratory infections

Publications (2)

Publication Number Publication Date
CA2962117A1 CA2962117A1 (en) 2016-03-31
CA2962117C true CA2962117C (en) 2023-04-25

Family

ID=51869352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2962117A Active CA2962117C (en) 2014-09-23 2015-09-22 Pulmonary administration of pyocins for treating bacterial respiratory infections

Country Status (7)

Country Link
US (2) US11643442B2 (enExample)
EP (1) EP3200813B1 (enExample)
JP (1) JP6836506B2 (enExample)
CN (1) CN107073073B (enExample)
CA (1) CA2962117C (enExample)
GB (1) GB201416788D0 (enExample)
WO (1) WO2016046218A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111770687A (zh) * 2017-12-14 2020-10-13 拜克多科利尔私人控股有限公司 治疗性细菌素
US20220024992A1 (en) * 2018-11-02 2022-01-27 The Rockefeller University Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
WO2020104397A1 (en) * 2018-11-19 2020-05-28 Bioaster Methods and reagents for multiplex binding experiments
AU2020287918A1 (en) * 2019-06-06 2021-12-16 Nomad Bioscience Gmbh Klebicins for the control of Klebsiella
EP4248987A1 (en) * 2022-03-21 2023-09-27 Nomad Bioscience GmbH Chimeric bacteriocins and method for the control of pseudomonas
CN121135836A (zh) * 2024-06-14 2025-12-16 无锡佰翱得生物科学股份有限公司 一种绿脓杆菌免疫蛋白及其应用
CN121135834A (zh) * 2024-06-14 2025-12-16 无锡佰翱得生物科学股份有限公司 一种绿脓杆菌InA蛋白及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861754A (en) 1986-05-28 1989-08-29 Farkas Himsley Hannah Bacteriocins and compositions thereof in anti-viral treatment
JP3655645B2 (ja) * 1992-02-28 2005-06-02 中外製薬株式会社 経粘膜投与剤
WO1998020836A2 (en) 1996-11-15 1998-05-22 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
AU7572900A (en) * 1999-08-26 2001-03-19 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
US20060229244A1 (en) * 2004-09-27 2006-10-12 Robert Dorit Engineered bacteriocins and bacteriocin combinations and methods for treating bacterial based infections
US7700729B2 (en) * 2006-05-15 2010-04-20 Avidbiotics Corporation Modified bacteriocins and methods for their use
CA2652450C (en) * 2006-05-15 2013-10-15 Avidbiotics Corporation Modified bacteriocins and methods for their use
US20110129438A1 (en) * 2006-06-28 2011-06-02 James Robert Swartz Immunogenic protein constructs
US20080286236A1 (en) * 2007-05-14 2008-11-20 Avidbiotics Corporation Inhibition of yersinia pestis
WO2012140676A2 (en) * 2011-04-12 2012-10-18 Appaiah C B Chimeric antibacterial polypeptides
GB201116234D0 (en) * 2011-09-20 2011-11-02 Aseptika Ltd Biomarkers for respiratory infection

Also Published As

Publication number Publication date
US12162911B2 (en) 2024-12-10
EP3200813A1 (en) 2017-08-09
US20230303636A1 (en) 2023-09-28
CN107073073A (zh) 2017-08-18
CA2962117A1 (en) 2016-03-31
US11643442B2 (en) 2023-05-09
CN107073073B (zh) 2021-07-09
GB201416788D0 (en) 2014-11-05
EP3200813B1 (en) 2021-04-07
JP6836506B2 (ja) 2021-03-03
JP2017529398A (ja) 2017-10-05
US20170240602A1 (en) 2017-08-24
WO2016046218A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
US12162911B2 (en) Pulmonary administration of pyocins for treating bacterial respiratory infections
Lee et al. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options
Waters et al. Cystic fibrosis microbiology: advances in antimicrobial therapy
CN116077630A (zh) 具有对抗革兰氏阴性菌的活性的溶素多肽
Egan et al. Bacteriocins: antibiotics in the age of the microbiome
JP2024010053A (ja) シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定
US11207378B2 (en) Compositions for inhibiting formation of and/or disrupting bacterial biofilms and methods of use therefor
Dicks et al. Medical and personal care applications of bacteriocins produced by lactic acid bacteria
WO2014009744A1 (en) Colicins for treating bacterial infections
JP2026031930A (ja) クレブシエラの制御のためのクレビシン
Kang et al. PEP27-2, a potent antimicrobial cell-penetrating peptide, reduces skin abscess formation during Staphylococcus aureus infections in mouse when used in combination with antibiotics
KR20210024005A (ko) 스태필로코커스 아우레우스 및 그람 양성 세균을 항생제에 재민감화시키기 위한 리신 및 이의 유도체
CN114401735A (zh) 抗微生物的、细菌噬菌体来源的多肽及其针对革兰氏阴性和抗酸细菌的用途
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
JP5934225B2 (ja) 抗微生物タンパク質
HK1241754B (en) Pulmonary administration of pyocins for treating bacterial respiratory infections
Mmbando et al. Current approaches and tools for combating antibiotic resistance
Singh et al. Bacteriocins and antimicrobial peptides
US20210052679A1 (en) Probiotic delivery of guided antimicrobial peptides
Sharma et al. Antimicrobial Resistance in Acinetobacter baumannii: A Challenge to Clinical Settings
Romanova et al. Review of alternative antimicrobial therapies
WO2020093057A1 (en) Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
Lee Lee JH, Park M, Park KS, Bae IK, Kim YB, Cha CJ, Jeong BC and Lee SH (2017) Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options
Paškevičius Development and synthesis of plant-derived recombinant biopharmaceutical proteins active against gram-negative pathogenic bacteria
Amiss Investigating the use of cell-penetrating peptides to target bacteria inside host cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200910

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240910

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240910

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240910

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250910

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250910